Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of molecularly-targeted radiation (MTR) therapy. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
Our mission is
to help patients
with cancer live longer
with better quality lives
Molecularly-targeted radiation (MTR) against PSMA is coming and good to see this technology getting traction. @Telixpharma is committed to moving the field by providing PSMA imaging technology for the $ECYT US Phase III trial.